Dr. Francine Ducharme, University of Montréal, Montréal, QC
Inhaled corticosteroids form the bedrock of asthma therapies, but worries about a potential effect on growth has lead to interest in intermittent use of ICS in children. Adding other medications to reduce symptoms and improve health-related outcomes have shown often different results from than observed in adults. The evidence supporting the safety and efficacy of various monotherapies and addon therapies to inhaled corticosteroids will be explored. The efficacy of novel therapeutic approaches such as anti-IgE and tiotropium for specific childhood phenotypes will be reviewed and evaluated in the context of systematic reviews of randomized trials.
At the end of this presentation, attendees will be able to:
- review the evidence supporting the safety and efficacy;
- appraise the impact of adjunct therapy to ICS in children; and
- examine the evidence supporting anti-IgE and novel therapeutic approaches in this age group.